- Former CFO of Xcellerex, Inc. Joins Repligen Executive Management
Team -
WALTHAM, Mass.--(BUSINESS WIRE)--
Repligen Corporation (NASDAQ:RGEN) today announced the appointment of
Jonathan I. Lieber to the position of Chief Financial Officer and
Treasurer, effective immediately. Mr. Lieber most recently held the
position of CFO and Treasurer at Xcellerex, Inc., a supplier of
bioprocessing products and disposable biomanufacturing technologies,
which was acquired in May 2012 by GE Healthcare. He will be responsible
for leading Repligen’s financial activities, including long-term
financial strategy and risk management. Repligen’s current CFO William
J. Kelly has been named Chief Accounting Officer, overseeing the
Company’s accounting and management reporting functions, as well as its
internal controls.
“We are pleased to welcome Jonathan Lieber to the CFO role,” said Walter
C. Herlihy, Ph.D., President and Chief Executive Officer at Repligen.
“Over the past nine months, Repligen has become a profitable,
significantly larger and more complex multinational organization. As the
Company enters its next phase of growth, Mr. Lieber brings a
particularly relevant skill set to the management team. His combined
life sciences and capital markets expertise will be major assets to the
Company as we advance on our strategy to further expand Repligen’s
bioprocessing business and deliver top-tier financial performance.”
During his three-year tenure with Xcellerex, Mr. Lieber led the
company’s accounting, finance, legal and corporate communications
activities. He restructured the finance department and implemented
business processes to support substantial revenue growth. Prior to his
role with Xcellerex, Mr. Lieber was with Altus Pharmaceuticals for seven
years, most recently as Senior Vice President, CFO and Treasurer. At
Altus, he had responsibility for accounting and finance, and for
managing several administrative departments. Mr. Lieber led all capital
raising activities at the company, resulting in net proceeds to Altus of
$250 million, including its $110 million initial public offering. Prior
to joining Altus, Mr. Lieber served as vice president of SG Cowen’s
Healthcare Investment Banking Group, where he originated and executed on
multiple corporate financings and merger & acquisition transactions. Mr.
Lieber has been involved in healthcare financings totaling over $3
billion in common stock and over $500 million in initial public
offerings. He received a B.S. in business administration and finance
from Boston University and an M.B.A. in finance from New York University
Stern School of Business.
In connection with Mr. Lieber’s appointment, Repligen granted Mr. Lieber
an inducement equity award outside of Repligen’s 2012 Stock Option and
Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). This
award, which was approved by Repligen’s compensation committee and is
consistent with Repligen’s past practice for new executive hires, is for
15,000 shares of restricted stock which will vest in full on the first
anniversary of Mr. Lieber’s start date with Repligen.
About Repligen Corporation
Repligen Corporation is a life sciences company focused on the
development, production and commercialization of products used in the
process of manufacturing biological drugs. Our bioprocessing products
are sold to major life sciences and biopharmaceutical companies
worldwide. We are a leading manufacturer of Protein A, a critical
reagent used to manufacture monoclonal antibody-based therapeutics. We
also supply several growth factor products used to increase cell culture
productivity in biomanufacturing. In the burgeoning area of disposable
biomanufacturing technologies, we have developed and market a series of
OPUS™ (Open Platform User Specified) single-use chromatography columns
used in the biologics purification process. In addition to our core
bioprocessing business, we have a portfolio of clinical-stage partnering
assets, including two central nervous system orphan drug candidates and
a pancreatic imaging agent in Phase 3 development. Repligen’s corporate
headquarters are located in Waltham, MA, USA; we have an additional
manufacturing facility in Lund, Sweden. For more information, please
visit our website at www.repligen.com.
This press release contains forward-looking statements, which are
made pursuant to the safe harbor provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. Investors are cautioned that
statements in this press release which are not strictly historical
statements, including, without limitation, express or implied statements
regarding future financial performance and position, our strategic
decision to focus on the growth of our bioprocessing business, plans and
objectives for future operations, our ability to successfully negotiate
and consummate partnering transactions for our clinical stage assets,
including RG1068, RG3039 and RG2833, plans and objectives for product
development, our market share and product sales and other statements
identified by words like “believe,” “expect,” “may,” “will,” “should,”
“seek,” or “could” and similar expressions, constitute forward-looking
statements. Such forward-looking statements are subject to a number of
risks and uncertainties that could cause actual results to differ
materially from those anticipated, including, without limitation, risks
associated with: our ability to successfully grow our bioprocessing
business; our ability to successfully negotiate and consummate
development and commercialization partnerships for our portfolio of
therapeutic and diagnostic assets on acceptable terms, if at all; our
ability to develop and commercialize products and the market acceptance
of our products; reduced demand for our products that adversely impacts
our future revenues, cash flows, results of operations and financial
condition; our ability to obtain regulatory approvals; the success of
current and future collaborative or supply relationships; our ability to
compete with larger, better financed bioprocessing, pharmaceutical and
biotechnology companies; our ability to successfully integrate Repligen
Sweden AB; the success of our clinical trials; new approaches to the
treatment of our targeted diseases; our compliance with all FDA and EMEA
regulations; our ability to obtain, maintain and protect intellectual
property rights for our products; the risk of litigation regarding our
intellectual property rights; our limited sales capabilities; our
volatile stock price; and other risks detailed in Repligen’s Annual
Report on Form 10-K on file with the Securities and Exchange Commission
and the other reports that Repligen periodically files with the
Securities and Exchange Commission. Actual results may differ materially
from those Repligen contemplated by these forward-looking statements.
These forward looking statements reflect management’s current views and
Repligen does not undertake to update any of these forward-looking
statements to reflect a change in its views or events or circumstances
that occur after the date hereof except as required by law.
Repligen Corporation
Sondra S. Newman, 781-419-1881
Director
Investor Relations
snewman@repligen.com
Source: Repligen Corporation